Cold Agglutinin Disease (CAD) Treatment Market to Reach USD 986.73 Million by 2035, Driven by Sanofi, Novartis, Sobi & Apellis

The global Cold Agglutinin Disease (CAD) Treatment Market was valued at approximately USD 118.58 million in 2025 and is projected to reach USD 986.73 million by 2035, expanding at a CAGR of 23.6% during the forecast period 2026-2035. The market is entering a high-growth phase as the treatment landscape shifts from supportive care and off-label immunosuppression toward targeted complement therapies and disease-specific biologics. The approval and commercial adoption of sutimlimab (Enjaymo) have established a targeted-treatment category for CAD, while growing diagnosis of rare autoimmune hemolytic anemia is expanding the addressable patient population.

Investment activity is increasingly focused on next-generation, convenient, and potentially durable CAD therapies. A major commercial signal came when Recordati acquired global rights to Enjaymo from Sanofi for USD 825 million, with up to USD 250 million in additional commercial milestone payments, demonstrating the strategic value of targeted CAD treatments. Meanwhile, Annexon is advancing ANX1502, an oral C1s inhibitor, through a proof-of-concept study in CAD, with clinical updates anticipated in 2026. Biohaven is also developing BHV-1490, an IgM-degrading therapy designed to address IgM-mediated diseases including CAD. The competitive opportunity is therefore shifting toward oral administration, longer-lasting disease control, reduced infusion burden, and precision targeting, making CAD one of the more closely watched rare-disease treatment markets.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/cold-agglutinin-disease-treatment-market?sai-v

Recent Developments
June 2026: Recordati continued advancing the CADENCE real-world evidence registry, which tracks patients with cold agglutinin disease and cold agglutinin syndrome across multiple countries. The registry is generating longitudinal evidence on treatment patterns, disease burden, and outcomes, supporting improved long-term management of CAD.

May 2026: Sanofi continued strengthening the clinical and commercial presence of Enjaymo (sutimlimab), a C1s inhibitor that targets classical complement pathway activation and hemolysis in adults with CAD. The therapy remains a key targeted treatment option across North America and Europe, reinforcing complement inhibition as a central strategy in CAD management.

April 2026: Sobi continued development of pegcetacoplan as a potential treatment for CAD. The investigational therapy targets complement component C3 and is being evaluated for its ability to improve hemoglobin levels, reduce hemolysis, and decrease transfusion requirements, reflecting growing interest in therapies acting at different points of the complement pathway.

March 2026: Sanofi continued evaluation of SAR445088 in CAD through its long-term clinical program, assessing sustained safety, pharmacodynamic effects, and complement-mediated hemolysis. Although the Phase I study has completed, the program illustrates continued exploration of alternative complement-targeting approaches for CAD.

February 2026: The CAD treatment pipeline continued shifting toward targeted complement therapies, with C1s, C3, and alternative-pathway inhibition being explored to provide more effective control of hemolysis and reduce transfusion dependence. This development is particularly significant across North America and Europe, where increasing clinical experience with complement inhibitors is supporting more targeted approaches to CAD management.

Key Players
Sanofi | Novartis AG | Swedish Orphan Biovitrum AB | Apellis Pharmaceuticals, Inc. | Alexion Pharmaceuticals, Inc. | Genentech USA, Inc. | Alpine Immune Sciences | NovelMed Inc. | Teva Pharmaceuticals USA, Inc. | Viatris Inc. | Others

Key Highlights
Sanofi - Holds a 21.4% share, driven by its rare disease portfolio, complement pathway expertise, innovative hematology therapies, and global commercialization capabilities.

Novartis AG - Holds a 17.8% share, supported by its advanced immunology and hematology portfolio, complement-targeted research, and focus on innovative treatments for rare blood disorders.

Swedish Orphan Biovitrum AB (Sobi) - Holds a 15.6% share, strengthened by its specialized rare disease and hematology portfolio, complement-mediated disease expertise, and global commercialization network.

Apellis Pharmaceuticals, Inc. - Holds a 13.2% share, fueled by its complement C3-targeted therapeutic platform and focus on developing treatments for complement-driven diseases.

Alexion Pharmaceuticals, Inc. - Holds a 10.7% share, driven by its established expertise in complement biology, rare disease therapies, and development of targeted complement inhibitors.

Genentech USA, Inc. - Holds a 7.4% share, supported by its biologics development capabilities, immunology and hematology portfolio, and strong clinical research infrastructure.

Alpine Immune Sciences - Holds a 4.8% share, strengthened by its protein engineering platform and development of innovative immune-modulating therapies targeting complement and immune pathways.

NovelMed Inc. - Holds a 3.1% share, driven by its focus on complement-targeted therapeutics and development programs addressing complement-mediated hematological disorders.

Teva Pharmaceuticals USA, Inc. - Holds a 2.9% share, supported by its broad specialty pharmaceutical portfolio, biosimilar capabilities, and global presence in hematology and immune-mediated diseases.

Viatris Inc. - Holds a 1.8% share, fueled by its broad pharmaceutical portfolio, specialty medicines, and extensive global distribution capabilities.

Others - Hold a combined 1.3% share, comprising emerging biotechnology companies, specialty pharmaceutical firms, complement-pathway drug developers, and regional manufacturers advancing targeted therapies for Cold Agglutinin Disease.

Get the Full Report Here: https://www.datamintelligence.com/buy-now-page?report=cold-agglutinin-disease-treatment-market?sai-v

Market Drivers
Rising awareness and diagnosis of rare autoimmune hemolytic anemia, along with increasing demand for targeted therapies, are driving the CAD treatment market.

Advancements in complement-pathway research, biomarker testing, and personalized treatment are expanding therapeutic opportunities.

The global CAD treatment market was valued at USD 118.58 million in 2025 and is projected to reach USD 986.73 million by 2035, growing at a 23.6% CAGR.

Market Opportunities
Growing demand for next-generation complement inhibitors and longer-acting therapies is creating new opportunities.

Increasing investments in rare-disease diagnostics, complement testing, and targeted drug development are expanding market potential.

Development of convenient administration options and therapies targeting different stages of complement activation is supporting innovation.

Strategic collaborations and commercialization agreements are strengthening the CAD treatment pipeline

Recordati agreed to acquire global rights to Enjaymo from Sanofi for USD 825 million, plus potential milestones.

Industry Developments
Complement inhibitors and precision diagnostics are transforming the CAD treatment landscape.

Continued commercialization and clinical development of complement-pathway therapies are supporting expansion of targeted CAD treatment.

Enjaymo remains an FDA-approved targeted treatment for reducing hemolysis in adults with CAD.

Regulatory activities, clinical research, strategic partnerships, and new complement-targeting therapies are strengthening competition.

Regional Insights
North America 40.6% share: Leads the market due to advanced rare-disease diagnosis, strong healthcare infrastructure, high adoption of targeted therapies, and significant pharmaceutical R&D.

Europe 29.2% share: Growth is supported by established rare-disease programs, specialist hematology services, increasing diagnosis, and adoption of complement-targeted therapies.

Asia Pacific 23.1% share: Fastest-growing region, driven by improving rare-disease diagnosis, expanding healthcare infrastructure, increasing awareness, and rising pharmaceutical investments.

Latin America 4.0% share: Supported by improving access to specialized hematology care, expanding diagnostic capabilities, and growing awareness of CAD.

Middle East & Africa 3.1% share: Driven by healthcare modernization, improving diagnosis of rare blood disorders, and increasing access to advanced treatments.

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/cold-agglutinin-disease-treatment-market?sai-v

Key Segments
➥ By Type

Primary Cold Agglutinin Disease: Represents the dominant segment, driven by increasing recognition of complement-mediated hemolysis, growing availability of targeted therapies, and rising diagnosis of primary CAD as a distinct hematologic disorder.

Secondary Cold Agglutinin Disease: Represents a significant segment, supported by the association of CAD with underlying lymphoproliferative disorders, infections, autoimmune diseases, and other conditions requiring comprehensive disease management.

➥ By Drug Type

Biologics: Represents the dominant and fastest-growing segment, driven by increasing adoption of targeted complement therapies, improved clinical outcomes, and growing investment in novel biologic treatments for CAD.

Purine Analogue: Represents a significant segment, supported by its use in selected patients with underlying clonal B-cell disorders and the continued need for therapies targeting the disease-associated lymphoproliferative process.

Corticosteroid: Represents a moderate segment, driven by their historical use in managing autoimmune hemolytic conditions, although their role in primary CAD is limited compared with targeted therapies.

Alkylating Agents: Represents a significant segment, supported by their use in selected patients with CAD associated with underlying B-cell lymphoproliferative disorders.

Folic Acid Supplements: Represents a supportive segment, fueled by the need to address increased folate requirements associated with chronic hemolysis and red blood cell production.

Others: Represents a growing segment, supported by continued development of complement inhibitors, B-cell-directed therapies, plasma-based interventions, and emerging treatment approaches for CAD.

➥ By Route of Administration

Oral: Represents a significant segment, driven by the convenience of oral administration and continued use of corticosteroids, immunomodulatory agents, and other supportive therapies in CAD management.

Parenteral: Represents the dominant segment, fueled by increasing adoption of intravenous and subcutaneous targeted therapies, particularly biologic treatments requiring administration under medical supervision.

➥ By Distribution Channel

Hospital Pharmacies: Represents the dominant segment, driven by the specialized nature of CAD treatment, increasing use of biologic therapies, and the need for clinical monitoring during treatment initiation and management.

Retail Pharmacies: Represents a significant segment, supported by the availability of oral supportive medications and increasing outpatient management of patients with chronic CAD.

Online Pharmacies: Represents a rapidly growing segment, fueled by expanding digital pharmacy platforms, home-delivery services, improved access to specialty medications, and growing preference for convenient prescription fulfillment.

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.